Coloplast AS Class B
COLO B: XCSE (DNK)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| <rp | LOCK|C&QZ@ | LOCK|&!F@Fn! |
Coloplast Earnings: Typical Top-Line Growth Is Coupled With Margin Pressure; Maintaining Fair Value
Consistent with its long-term revenue growth profile, Coloplast delivered fiscal first-quarter top-line growth of 8%, though operating margin was held down at 27%.
